Compile Data Set for Download or QSAR
Report error Found 1648 of ic50 for UniProtKB: P28223
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM117016(US8664258, 32 | US9987252, 32)
Affinity DataIC50: 0.0250nMAssay Description:Radioligand binding assays for human 5-HT2A receptor was conducted using the 5-HT2 agonist [125I]DOI as radioligand. To define nonspecific binding, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM117016(US8664258, 32 | US9987252, 32)
Affinity DataIC50: 0.0250nMpH: 7.4 T: 2°CAssay Description:Radioligand binding assays for human 5-HT2A receptor was conducted using the 5-HT2 agonist [125]DOI as radioligand. To define nonspecific binding, 10...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2014
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM705326(US20240279226, Example 12)
Affinity DataIC50: 0.0400nMAssay Description:Compounds of the present application bind to the 5-HT2 receptor subtypes in the following assays: Compounds of the invention are tested on 5-HT2A and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50001775(cid_5074 | Ritanserine | 6-(2-{4-[Bis-(4-fluoro-ph...)
Affinity DataIC50: 0.0690nMAssay Description:R-SAT assays were performed as described previously (Weiner et al., 2001), with the following modifications. In brief, NIH-3T3 cells were grown to 80...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/20/2015
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM119676(US8680119, 15)
Affinity DataIC50: 0.0820nMpH: 7.4Assay Description:Radioligand binding assays for human 5-HT2A receptor was conducted using the 5-HT2 agonist [125I]DOI as radioligand. To define nonspecific binding, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/16/2014
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50547397(Lu 31-130 | Zicronapine | LU-31-130 | US12116355, ...)
Affinity DataIC50: 0.240nMAssay Description:The experiment was carried out at Cerep Contract Laboratories (Cat. ref. #471).Compound (I) was also tested in an in vivo set up demonstrating centra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50547397(Lu 31-130 | Zicronapine | LU-31-130 | US12116355, ...)
Affinity DataIC50: 0.25nMAssay Description:The experiment was carried out at Cerep Contract Laboratories (Cat. ref. #471).Compound (I) was also tested in an in vivo set up demonstrating centra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM783872(N-(Trans-4-(2-(4-(benzo[b]thiophen-4-yl)piperazin-...)
Affinity DataIC50: 0.260nMAssay Description:The assay buffer used in this screen is 0.05 M acetate, pH 4.2, 10% DMSO final, 100 uM genapol (which is a nonionic detergent, below its Critical Mic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/23/2026
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM783858(N-(Trans-4-(2-(4-(benzo[b]thiophen-4-yl)piperazin-...)
Affinity DataIC50: 0.260nMAssay Description:The assay buffer used in this screen is 0.05 M acetate, pH 4.2, 10% DMSO final, 100 uM genapol (which is a nonionic detergent, below its Critical Mic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/23/2026
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM117019(US8664258, 303 | US9987252, 303)
Affinity DataIC50: 0.260nMpH: 7.4 T: 2°CAssay Description:Radioligand binding assays for human 5-HT2A receptor was conducted using the 5-HT2 agonist [125]DOI as radioligand. To define nonspecific binding, 10...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2014
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM117019(US8664258, 303 | US9987252, 303)
Affinity DataIC50: 0.260nMAssay Description:Radioligand binding assays for human 5-HT2A receptor was conducted using the 5-HT2 agonist [125I]DOI as radioligand. To define nonspecific binding, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2020
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50649142(CHEMBL5618291)
Affinity DataIC50: 0.270nMAssay Description:Displacement of [3H]Ketanserin from recombinant human 5-HT2A receptor extracted from CHO cell membrane incubated for 60 mins by radioligand binding a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/12/2025
Entry Details
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM86525(NSC_77445 | CHEMBL79834 | CAS_77445 | AMI-193)
Affinity DataIC50: 0.316nMAssay Description:Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50547397(Lu 31-130 | Zicronapine | LU-31-130 | US12116355, ...)
Affinity DataIC50: 0.330nMAssay Description:The experiment was carried out at Cerep Contract Laboratories (Cat. ref. #471).Compound (I) was also tested in an in vivo set up demonstrating centra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM783879(N-(Trans-4-(2-(4-(benzo[b]thiophen-4-yl)piperazin-...)
Affinity DataIC50: 0.340nMAssay Description:The assay buffer used in this screen is 0.05 M acetate, pH 4.2, 10% DMSO final, 100 uM genapol (which is a nonionic detergent, below its Critical Mic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/23/2026
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM21395(3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}e...)
Affinity DataIC50: 0.350nMAssay Description:Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in HEK293 cells measured after 60 mins by scintillation counting metho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/3/2018
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM21395(3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}e...)
Affinity DataIC50: 0.350nMAssay Description:Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/9/2017
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM783873(N-(Trans-4-(2-(4-(benzo[b]thiophen-4-yl)piperazin-...)
Affinity DataIC50: 0.370nMAssay Description:The assay buffer used in this screen is 0.05 M acetate, pH 4.2, 10% DMSO final, 100 uM genapol (which is a nonionic detergent, below its Critical Mic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/23/2026
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50547397(Lu 31-130 | Zicronapine | LU-31-130 | US12116355, ...)
Affinity DataIC50: 0.370nMAssay Description:The experiment was carried out at Cerep Contract Laboratories (Cat. ref. #471).Compound (I) was also tested in an in vivo set up demonstrating centra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50540335(CHEMBL4635010)
Affinity DataIC50: 0.390nMAssay Description:Antagonist activity at 5HT2A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of serotonin hydrochloride-induced calcium fl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50048803(5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-et...)
Affinity DataIC50: 0.420nMAssay Description:Inhibitory concentration against 5-hydroxytryptamine 2 receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2012
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM783870(N-(Cis-4-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-...)
Affinity DataIC50: 0.430nMAssay Description:The assay buffer used in this screen is 0.05 M acetate, pH 4.2, 10% DMSO final, 100 uM genapol (which is a nonionic detergent, below its Critical Mic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/23/2026
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM783871(N-(Trans-4-(2-(4-(benzo[b]thiophen-4-yl)piperazin-...)
Affinity DataIC50: 0.430nMAssay Description:The assay buffer used in this screen is 0.05 M acetate, pH 4.2, 10% DMSO final, 100 uM genapol (which is a nonionic detergent, below its Critical Mic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/23/2026
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM616185(US20230277505, Compound 20 | 1-[3-(4-Bromo-2-methy...)
Affinity DataIC50: 0.450nMAssay Description:For total binding, a total volume of 50 ul of appropriately diluted membranes (diluted in assay buffer containing 50 mM Tris HCl (pH 7.4), 10 mM MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2023
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50306837(N-(Cyclohexylmethyl)-N-(3-(4-(4-fluorophenyl)piper...)
Affinity DataIC50: 0.5nMAssay Description:Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2010
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM119679(US8680119, 68)
Affinity DataIC50: 0.510nMpH: 7.4Assay Description:Radioligand binding assays for human 5-HT2A receptor was conducted using the 5-HT2 agonist [125I]DOI as radioligand. To define nonspecific binding, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/16/2014
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM21395(3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}e...)
Affinity DataIC50: 0.520nMAssay Description:Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor in HEK293 cells after 60 mins by scintillation countingMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/8/2019
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50596723(CHEMBL5205903 | US20230348421, Compound 59)
Affinity DataIC50: 0.540nMAssay Description:Antagonist activity at 5-HT2A receptor (unknown origin) expressed in CHO-K1 cells assessed as reduction in intracellular Ca2+ mobilization incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50556204(Lumateperone | ITI 007 | ITI-007 | ITI-722 | ITI00...)
Affinity DataIC50: 0.540nMAssay Description:Antagonist activity at 5HT2A receptor (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2022
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50596723(CHEMBL5205903 | US20230348421, Compound 59)
Affinity DataIC50: 0.540nMAssay Description:CHO-K1/5-HT2A cells in the logarithmic growth phase were seeded into a 384-well plate at a density of 10000 cells per well, and cultured in a 37° C.,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2023
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50540327(CHEMBL4644559)
Affinity DataIC50: 0.600nMAssay Description:Antagonist activity at 5HT2A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of serotonin hydrochloride-induced calcium fl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50464898(CHEMBL4287980)
Affinity DataIC50: 0.600nMAssay Description:Antagonist activity at 5-HT2A receptor (unknown origin) after 10 mins by calcium 5 dye based FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2020
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50547397(Lu 31-130 | Zicronapine | LU-31-130 | US12116355, ...)
Affinity DataIC50: 0.610nMAssay Description:The experiment was carried out at Cerep Contract Laboratories (Cat. ref. #471).Compound (I) was also tested in an in vivo set up demonstrating centra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50172414(2-(2,4-Dichloro-phenoxy)-N-[2-(2-dimethylamino-eth...)
Affinity DataIC50: 0.610nMAssay Description:Inhibitory concentration against 5-hydroxytryptamine 2A receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM783875(N-(Trans-4-(2-(4-(benzo[b]thiophen-4-yl)piperazin-...)
Affinity DataIC50: 0.630nMAssay Description:The assay buffer used in this screen is 0.05 M acetate, pH 4.2, 10% DMSO final, 100 uM genapol (which is a nonionic detergent, below its Critical Mic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/23/2026
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM392076(US10301272, Example 7/9)
Affinity DataIC50: 0.640nMAssay Description:Displacement of [3H]ketanserin human recombinant 5-HT2A receptor after 60 mins by scintillation counting analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/27/2020
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50306834(N-(Cyclohexylmethyl)-N-(3-(4-phenylpiperazin-1-yl)...)
Affinity DataIC50: 0.700nMAssay Description:Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in avCHO-K1 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
9/1/2010
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50001885(3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin...)
Affinity DataIC50: 0.708nMAssay Description:Antagonist activity at human 5HT2A receptor expressed in CHOK1 cells assessed as inhibition of 5-HT induced inositol phosphate production incubated f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50001885(3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin...)
Affinity DataIC50: 0.720nMAssay Description:Antagonist activity at human 5HT2A receptor expressed in CHOK1 cells assessed as inhibition of 5-HT induced inositol phosphate production incubated f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM689189(US20240254109, Example 7A | N-(Trans-3-(2-(4-(2,3-...)
Affinity DataIC50: 0.790nMAssay Description:5-HT2A Receptor: Experimental buffer: 50 mM Tris-HCl pH 7.4, 4 mM CaCl2); washing liquor: 50 mM Tris-HCl pH 7.4, stored at 4° C.; 0.5% PEI solution: ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50547397(Lu 31-130 | Zicronapine | LU-31-130 | US12116355, ...)
Affinity DataIC50: 0.790nMAssay Description:The experiment was carried out at Cerep Contract Laboratories (Cat. ref. #471).Compound (I) was also tested in an in vivo set up demonstrating centra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50194847(N-(1-ethylcyclopentyl)-7-(4-fluorophenyl)-2,3-dihy...)
Affinity DataIC50: 0.800nMAssay Description:Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50544628(CHEMBL4638006)
Affinity DataIC50: 0.810nMAssay Description:Antagonist activity at human 5HT2A receptor expressed in HEK293 cells assessed as inhibition of 5HT-induced intracellular Ca2+ mobilization incubated...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50544628(CHEMBL4638006)
Affinity DataIC50: 0.813nMAssay Description:Antagonist activity at human 5HT2A receptor expressed in HEK293 cells assessed as inhibition of 5HT-induced intracellular Ca2+ mobilization incubated...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM21395(3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}e...)
Affinity DataIC50: 0.820nMAssay Description:Displacement of [3H] ketanserin from human recombinant 5-HT2A receptor measured after 60 mins by scintillation counter methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2021
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM783878(N-(Trans-4-(2-(4-(benzo[b]thiophen-4-yl)piperazin-...)
Affinity DataIC50: 0.830nMAssay Description:The assay buffer used in this screen is 0.05 M acetate, pH 4.2, 10% DMSO final, 100 uM genapol (which is a nonionic detergent, below its Critical Mic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/23/2026
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50540334(CHEMBL4647697)
Affinity DataIC50: 0.870nMAssay Description:Antagonist activity at 5HT2A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of serotonin hydrochloride-induced calcium fl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMed
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM783881(N-(4-(2-(4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)e...)
Affinity DataIC50: 0.900nMAssay Description:The assay buffer used in this screen is 0.05 M acetate, pH 4.2, 10% DMSO final, 100 uM genapol (which is a nonionic detergent, below its Critical Mic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/23/2026
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM783876(N-(Trans-4-(2-(4-(benzo[b]thiophen-4-yl)piperazin-...)
Affinity DataIC50: 0.910nMAssay Description:The assay buffer used in this screen is 0.05 M acetate, pH 4.2, 10% DMSO final, 100 uM genapol (which is a nonionic detergent, below its Critical Mic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/23/2026
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM783877(N-(Trans-4-(2-(4-(benzo[b]thiophen-4-yl)piperazin-...)
Affinity DataIC50: 0.960nMAssay Description:The assay buffer used in this screen is 0.05 M acetate, pH 4.2, 10% DMSO final, 100 uM genapol (which is a nonionic detergent, below its Critical Mic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
2/23/2026
Entry Details
US Patent

Displayed 1 to 50 (of 1648 total ) | Next | Last >>
Jump to: